Impact of margin accentuation with intraoperative irreversible electroporation on local recurrence in resected pancreatic cancer

被引:5
作者
Martin II, Robert C. G. [1 ,2 ]
Schoen, Eric C. [1 ]
Philips, Prejesh [1 ]
Egger, Michael E. [1 ]
McMasters, Kelly M. [1 ]
Scoggins, Charles R. [1 ]
机构
[1] Univ Louisville, Sch Med, Hiram C Polk Jr MD Dept Surg, Div Surg Oncol, Louisville, KY 40202 USA
[2] Univ Louisville, Div Surg Oncol, 315 East Broadway, M-10,Room 311, Louisville, KY 40202 USA
关键词
DUCTAL ADENOCARCINOMA; NEOADJUVANT THERAPY; PANCREATICODUODENECTOMY; BORDERLINE; SURVIVAL; DISSECTION; MANAGEMENT; PATTERNS; ABLATION;
D O I
10.1016/j.surg.2022.07.033
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The purpose of this study was to evaluate the rates of local recurrence and margin positivity in patients with borderline resectable pancreatic cancer after pancreatectomy with or without irre-versible electroporation with margin accentuation.Methods: Prospective data for preoperative stages IIB (borderline resectable) and III were evaluated, with 75 patients undergoing pancreatectomy with irreversible electroporation with margin accentuation compared to 71 patients who underwent pancreatectomy alone from March 2010 to November 2020. Results: Both irreversible electroporation with margin accentuation and pancreatectomy-alone groups were similar for body mass index, Charleston comorbidity index, and sex. The irreversible electroporation with margin accentuation group had significantly greater preoperative stage III (irreversible electroporation 83% vs pancreatectomy alone 51%; P = .0001), with similar tumor location (head 64% vs 72%) and tumor size (median 2.9 vs 2.8). Neoadjuvant/induction chemotherapy and prior radiation therapy was similar in both groups (irreversible electroporation with margin accentuation 89% vs 72%). Surgical therapy included a greater percentage of pancreaticoduodenectomy in the pancreatectomy-alone group. Despite greater stage and greater percentage of margin positivity (irreversible electroporation with margin accentuation 27% vs 20%; P = not significant), rates of local recurrence were similar. The mean disease-free interval for local recurrence from time of diagnosis was similar (irreversible electroporation with margin accentuation 15.8 vs 16.5 pancreatectomy alone; P = not significant) and time of treatment (irreversible electroporation with margin accentuation 9.4 vs 10.5 months; P = not significant). Overall survival was improved with the irreversible electroporation with margin accentuation group, with a mean of 34.2 months versus 27.9 months in the pancreatectomy-alone group.Conclusion: Irreversible electroporation with margin accentuation is safe and effective in stages IIB and III pancreatic adenocarcinomas that are technically resectable. Despite higher margin positivity rates, the time to local recurrence and the effects of recurrence were the same in the pancreatectomy-alone group.(c) 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:581 / 589
页数:9
相关论文
共 45 条
  • [1] Whipple Made Simple For Surgical Pathologists Orientation, Dissection, and Sampling of Pancreaticoduodenectomy Specimens For a More Practical and Accurate Evaluation of Pancreatic, Distal Common Bile Duct, and Ampullary Tumors
    Adsay, N. Volkan
    Basturk, Olca
    Saka, Burcu
    Bagci, Pelin
    Ozdemir, Denizhan
    Balci, Serdar
    Sarmiento, Juan M.
    Kooby, David A.
    Staley, Charles
    Maithel, Shishir K.
    Everett, Rhonda
    Cheng, Jeanette D.
    Thirabanjasak, Duangpeng
    Weaver, Donald W.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2014, 38 (04) : 480 - 493
  • [2] The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging
    Amin, Mahul B.
    Greene, Frederick L.
    Edge, Stephen B.
    Compton, Carolyn C.
    Gershenwald, Jeffrey E.
    Brookland, Robert K.
    Meyer, Laura
    Gress, Donna M.
    Byrd, David R.
    Winchester, David P.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (02) : 93 - 99
  • [3] CT imaging of early local recurrence of pancreatic adenocarcinoma following pancreaticoduodenectomy
    Balaj, Clemence
    Ayav, Ahmet
    Oliver, Alexandre
    Jausset, Francois
    Sellal, Caroline
    Claudon, Michel
    Laurent, Valeie
    [J]. ABDOMINAL RADIOLOGY, 2016, 41 (02) : 273 - 282
  • [4] Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer
    Barnes, Chad A.
    Aldakkak, Mohammed
    Christians, Kathleen K.
    Clarke, Callisia N.
    Dua, Kulwinder
    George, Ben
    Ritch, Paul S.
    Kamgar, Mandana
    Hall, William A.
    Kulkarni, Naveen
    Erickson, Beth A.
    Evans, Douglas B.
    Tsai, Susan
    [J]. SURGERY, 2020, 168 (03) : 440 - 447
  • [5] Hepatobiliary Cancers, Version 2.2021
    Benson III, Al B.
    D'Angelica, Michael I.
    Abbott, Daniel E.
    Anaya, Daniel A.
    Anders, Robert
    Are, Chandrakanth
    Bachini, Melinda
    Borad, Mitesh
    Brown, Daniel
    Burgoyne, Adam
    Chahal, Prabhleen
    Chang, Daniel T.
    Cloyd, Jordan
    Covey, Anne M.
    Glazer, Evan S.
    Goyal, Lipika
    Hawkins, William G.
    Iyer, Renuka
    Jacob, Rojymon
    Kelley, R. Kate
    Kim, Robin
    Levine, Matthew
    Palta, Manisha
    Park, James O.
    Raman, Steven
    Reddy, Sanjay
    Sahai, Vaibhav
    Schefter, Tracey
    Singh, Gagandeep
    Stein, Stacey
    Vauthey, Jean-Nicolas
    Venook, Alan P.
    Yopp, Adam
    McMillian, Nicole R.
    Hochstetler, Cindy
    Darlow, Susan D.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (05): : 541 - 565
  • [6] Irreversible Electroporation of the Pancreas: Definitive Local Therapy Without Systemic Effects
    Bower, Matthew
    Sherwood, Leslie
    Li, Yan
    Martin, Robert
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2011, 104 (01) : 22 - 28
  • [7] A systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for pancreatic adenocarcinoma
    Butler, James R.
    Ahmad, Syed A.
    Katz, Matthew H.
    Cioffi, Jessica L.
    Zyromski, Nicholas J.
    [J]. HPB, 2016, 18 (04) : 305 - 311
  • [8] Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
    Callery, Mark P.
    Chang, Kenneth J.
    Fishman, Elliot K.
    Talamonti, Mark S.
    Traverso, L. William
    Linehan, David C.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (07) : 1727 - 1733
  • [9] The Clavien-Dindo Classification of Surgical Complications Five-Year Experience
    Clavien, Pierre A.
    Barkun, Jeffrey
    de Oliveira, Michelle L.
    Vauthey, Jean Nicolas
    Dindo, Daniel
    Schulick, Richard D.
    de Santibanes, Eduardo
    Pekolj, Juan
    Slankamenac, Ksenija
    Bassi, Claudio
    Graf, Rolf
    Vonlanthen, Rene
    Padbury, Robert
    Cameron, John L.
    Makuuchi, Masatoshi
    [J]. ANNALS OF SURGERY, 2009, 250 (02) : 187 - 196
  • [10] FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
    Conroy, T.
    Hammel, P.
    Hebbar, M.
    Ben Abdelghani, M.
    Wei, A. C.
    Raoul, J. -L.
    Chone, L.
    Francois, E.
    Artru, P.
    Biagi, J. J.
    Lecomte, T.
    Assenat, E.
    Faroux, R.
    Ychou, M.
    Volet, J.
    Sauvanet, A.
    Breysacher, G.
    Di Fiore, F.
    Cripps, C.
    Kavan, P.
    Texereau, P.
    Bouhier-Leporrier, K.
    Khemissa-Akouz, F.
    Legoux, J. -L.
    Juzyna, B.
    Gourgou, S.
    O'Callaghan, C. J.
    Jouffroy-Zeller, C.
    Rat, P.
    Malka, D.
    Castan, F.
    Bachet, J. -B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25) : 2395 - 2406